Sorafenib Gastric Cancer Asian Phase I Study
This study is to investigate safety, pharmacokinetics and preliminary efficacy profile of sorafenib in combination with S-1 plus cisplatin in Asian patients with unresectable / recurrent gastric cancer.
Gastric Cancer
DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Sorafenib (Nexavar, BAY43-9006)
Safety and pharmacokinetics, 20 weeks after start of treatment
1 year survival rate, 1 year after start of treatment|Overall survival, 1 year after start of treatment|Progression free survival, 1 year after start of treatment|Response rate, 1 year after start of treatment|Duration of response, Time from initial Response to documented Tumor Progression
This study is to investigate safety, pharmacokinetics and preliminary efficacy profile of sorafenib in combination with S-1 plus cisplatin in Asian patients with unresectable / recurrent gastric cancer.